NCT00459979View on ClinicalTrials.gov

Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

March 31, 2011

Study Completion Date

September 30, 2013

Conditions
Kidney Cancer
Interventions
DRUG

sunitinib malate

Sunitinib will be dosed at 50 mg p.o. daily

PROCEDURE

conventional surgery

nephrectomy

Trial Locations (1)

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT00459979 - Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter